Genfit Sa (GNFT)

$5.46

+0.07

(+1.37%)

Market is closed - opens 7 PM, 08 Oct 2024

Performance

  • $5.45
    $5.65
    $5.46
    downward going graph

    0.18%

    Downside

    Day's Volatility :3.54%

    Upside

    3.36%

    downward going graph
  • $2.89
    $6.05
    $5.46
    downward going graph

    47.01%

    Downside

    52 Weeks Volatility :52.17%

    Upside

    9.75%

    downward going graph

Returns

PeriodGenfit SaIndex (Russel 2000)
3 Months
23.82%
0.0%
6 Months
55.67%
0.0%
1 Year
79.54%
0.0%
3 Years
46.76%
-21.4%

Highlights

Market Capitalization
268.8M
Book Value
$1.96
Earnings Per Share (EPS)
0.41
PE Ratio
13.14
Profit Margin
27.68%
Operating Margin TTM
51.0%
Return On Assets TTM
6.51%
Return On Equity TTM
25.91%
Revenue TTM
80.5M
Revenue Per Share TTM
1.62
Quarterly Revenue Growth YOY
304.4%
Gross Profit TTM
26.2M
EBITDA
21.9M
Diluted Eps TTM
0.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Genfit Sa(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Company Financials

FY18Y/Y Change
Revenue
78.5K
↓ 41.53%
Net Income
-90.5M
↑ 35.69%
Net Profit Margin
-115.2K%
↓ 65583.42%
FY19Y/Y Change
Revenue
34.3M
↑ 44594.2%
Net Income
-72.4M
↓ 18.08%
Net Profit Margin
-211.24%
↑ 115036.59%
FY20Y/Y Change
Revenue
930.5K
↓ 97.52%
Net Income
-123.1M
↑ 55.38%
Net Profit Margin
-13.2K%
↓ 13020.26%
FY21Y/Y Change
Revenue
90.5M
↑ 10366.54%
Net Income
76.0M
↓ 166.45%
Net Profit Margin
84.0%
↑ 13315.5%
FY22Y/Y Change
Revenue
21.4M
↓ 74.78%
Net Income
-25.1M
↓ 135.27%
Net Profit Margin
-117.45%
↓ 201.45%
FY23Y/Y Change
Revenue
31.2M
↑ 41.45%
Net Income
-31.5M
↑ 21.81%
Net Profit Margin
-101.15%
↑ 16.3%
Q1 FY23Q/Q Change
Revenue
7.6M
↑ 23.97%
Net Income
-10.4M
-
Net Profit Margin
-138.0%
-
Q2 FY23Q/Q Change
Revenue
11.5M
↑ 51.96%
Net Income
-20.9M
↑ 100.0%
Net Profit Margin
-181.62%
↓ 43.62%
Q3 FY23Q/Q Change
Revenue
3.0M
↓ 75.46%
Net Income
-4.3M
↓ 80.72%
Net Profit Margin
-142.65%
↑ 38.97%
Q1 FY24Q/Q Change
Revenue
17.1M
↑ 19.75%
Net Income
-8.0M
-
Net Profit Margin
-47.06%
-
FY18Y/Y Change
Total Assets
261.0M
↓ 21.73%
Total Liabilities
237.2M
↑ 10.36%
FY19Y/Y Change
Total Assets
344.3M
↑ 35.03%
Total Liabilities
250.9M
↑ 8.27%
FY20Y/Y Change
Total Assets
241.6M
↓ 35.9%
Total Liabilities
261.2M
↓ 4.88%
FY21Y/Y Change
Total Assets
318.5M
↑ 41.84%
Total Liabilities
183.8M
↓ 24.28%
FY22Y/Y Change
Total Assets
228.1M
↓ 23.49%
Total Liabilities
128.1M
↓ 25.59%
FY23Y/Y Change
Total Assets
173.3M
↓ 19.58%
Total Liabilities
105.9M
↓ 12.47%
Q4 FY22Q/Q Change
Total Assets
228.1M
-
Total Liabilities
128.1M
-
Q1 FY23Q/Q Change
Total Assets
207.5M
↓ 10.04%
Total Liabilities
127.8M
↓ 1.34%
Q2 FY23Q/Q Change
Total Assets
210.3M
↑ 0.0%
Total Liabilities
129.5M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
173.9M
↓ 10.33%
Total Liabilities
105.9M
↓ 11.28%
Q4 FY23Q/Q Change
Total Assets
189.7M
↑ 0.0%
Total Liabilities
115.5M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
173.3M
↓ 0.3%
Total Liabilities
105.9M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-63.8M
↑ 12.49%
Investing Cash Flow
-4.5M
↑ 35.21%
Financing Cash Flow
-7.4M
↓ 103.74%
FY19Y/Y Change
Operating Cash Flow
-53.0M
↓ 14.98%
Investing Cash Flow
363.4K
↓ 108.2%
Financing Cash Flow
129.9M
↓ 1893.98%
FY20Y/Y Change
Operating Cash Flow
-117.2M
↑ 102.12%
Investing Cash Flow
-1.2M
↓ 395.41%
Financing Cash Flow
-10.0M
↓ 107.06%
FY21Y/Y Change
Operating Cash Flow
112.9M
↓ 203.68%
Investing Cash Flow
-3.8M
↑ 249.59%
Financing Cash Flow
-10.1M
↑ 7.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-12.6M
↓ 74.1%
Investing Cash Flow
1.3M
↓ 1447.74%
Financing Cash Flow
-921.5K
↑ 2.05%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.5M
↓ 0.26%
Investing Cash Flow
1.3M
↑ 0.0%
Financing Cash Flow
-882.0K
↓ 4.29%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.5M
↑ 0.0%
Investing Cash Flow
1.3M
↑ 0.0%
Financing Cash Flow
-882.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-25.8M
↑ 106.13%
Investing Cash Flow
1.3M
↑ 0.0%
Financing Cash Flow
-995.0K
↑ 12.81%

Technicals Summary

Sell

Neutral

Buy

Genfit Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Genfit Sa
Genfit Sa
31.37%
55.67%
79.54%
46.76%
-60.4%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.53%
7.92%
21.76%
83.48%
256.87%
Novo Nordisk A/s
Novo Nordisk A/s
-12.73%
-9.68%
25.05%
134.03%
343.37%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.86%
71.74%
59.21%
32.07%
248.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.35%
12.64%
28.18%
152.92%
164.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Genfit Sa
Genfit Sa
13.14
13.14
NA
0.0
0.26
0.07
NA
1.96
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Genfit Sa
Genfit Sa
Buy
$268.8M
-60.4%
13.14
27.68%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
256.87%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
343.37%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.4B
248.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
164.64%
32.84
-4.74%

Insights on Genfit Sa

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.81M → 17.08M (in $), with an average increase of 48.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.01M → -8.03M (in $), with an average decrease of 100.0% per quarter

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    0.07%
  • OLD MISSION CAPITAL LLC

    0.03%

Company Information

genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.

Organization
Genfit Sa
Employees
169
CEO
Mr. Jean-Francois Mouney
Industry
Biotechnology

FAQs